News | March 13, 2008

Chemoembolization Used in 85 Percent of Liver Cancer Cases, Study Says

March 14, 2008 - Data from Millennium Research Group’s (MRG) U.S. Interventional Radiology (IR) Marketrack indicates that in 2007, over 85 percent of liver cancer treatments performed in IR suites used transcatheter chemoembolization, a procedure that delivers chemotherapy agents directly to a tumor through minimally invasive means.

Microsphere particles, including Boston Scientific’s Contour SE, Biosphere Medical’s Embosphere, and others, were used in 40 percent of these treatments. Overall, chemoembolization particles generated nearly 20 percent of total microsphere revenue. As such, chemoembolization procedures are a key segment in the overall embolic particle market, which, in addition to standard microspheres, includes drug-infused microspheres, selective internal radiation therapy (SIRT) spheres, and polyvinyl alcohol (PVA) particles. MRG’s US IR Marketrack service monitors the adoption of embolic particles for liver cancer, uterine fibroids, aneurysms, hemorrhages, and vascular anomalies.

“In chemoembolization, chemotherapy agents are mixed with embolic particles and are delivered through a catheter directly to the tumor, thereby localizing the chemo treatment,” said Phil Scrutton, Analyst at MRG. “The particles also embolize the surrounding arteries, blocking blood flow to the cancerous tissue. This slows diffusion of the chemotherapy agents away from the tumor, which increases its effectiveness in targeting the liver tumor, while the embolization also deprives the tumor of oxygen and nutrients.”

Liver cancer has historically had a poor prognosis, but the use of embolic particles in conjunction with drugs in chemoembolization, while not a cure, is leading to longer life expectancies for cancer sufferers. These positive clinical outcomes, the availability of improved embolization technologies and an increasing rate of patient referrals for this treatment are all contributing to embolic particle market growth.

For more information: www.MRG.net

Related Content

MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016
Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a...
BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer
News | Interventional Radiology | February 09, 2016
BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first...
Overlay Init